Background
Inositol was first isolated in the 19th century as a component of brain and muscle tissue and was later characterized as a cyclic polyol. Its role in phosphatidylinositol signaling was established in the mid-20th century, and the function of IP3 as a calcium-mobilizing second messenger was described in foundational work by Berridge and colleagues in the 1980s. Clinical interest in supplemental inositol grew in the late 20th century when stereoisomers were investigated for insulin resistance, PCOS, and psychiatric conditions. Research activity has continued, with numerous small RCTs and several systematic reviews now focused on reproductive and metabolic outcomes.
Evidence snapshot
Myo-inositol is well studied in women with PCOS. Multiple randomized controlled trials report that 4 g/day (typically 2 g twice daily) improves ovulation rate, menstrual regularity, and some metabolic parameters including fasting insulin and insulin resistance compared with placebo or baseline. Effect sizes vary and many trials are small, but the direction of evidence is consistent.
Clinical trials have tested high oral doses of inositol (12–18 g/day) for panic disorder and related anxiety endpoints. Benefits for panic attack frequency have been reported in some trials; results are heterogeneous across populations and designs, and the evidence is less consistent than for PCOS.
D-chiro-inositol and fixed-ratio combinations of myo- and D-chiro-inositol have been studied for metabolic and reproductive outcomes in PCOS. Tissue-specific stereoisomer ratios are biologically relevant, and some trial data suggest combined regimens offer advantages over either isomer alone. Short-term use (weeks to months) at doses used in research is generally well tolerated; data beyond 12 months are sparse.
Bioavailability and forms
Myo-inositol is absorbed in the small intestine and distributes broadly, including to the ovaries and brain. Supplemental forms include free myo-inositol powder and fixed-ratio combinations with D-chiro-inositol. Inositol hexaphosphate (IP6, phytic acid) is a phosphorylated plant-derived form with different pharmacokinetics; it is not interchangeable with free myo-inositol for PCOS or anxiety indications. Phosphatidylinositol supplements also exist but are pharmacologically distinct.
Populations studied
Most clinical trials enrolled reproductive-age women with PCOS, including those pursuing natural conception or assisted reproduction. Separate trials assessed metabolic outcomes in insulin resistance and gestational diabetes prevention. Psychiatric trials enrolled adults with panic disorder or obsessive-compulsive disorder. Evidence in men and in older adults is limited; most dosing guidance derives from female PCOS populations.
Long-term safety
Short-term use (weeks to months) of myo-inositol at 2–4 g/day is well tolerated across published trials, with gastrointestinal side effects being the most frequently reported adverse events. Data beyond 12 months are sparse. Doses of ≥12 g/day, used experimentally for psychiatric indications, produce more frequent gastrointestinal complaints. Use in pregnancy at 4 g/day has been studied for gestational diabetes prevention in several trials, but obstetric supervision remains advisable given limited long-term fetal safety data.
Comparisons and combinations
Myo-inositol has been compared with metformin for PCOS-related outcomes in several small trials, with broadly similar effects on ovulation and metabolic markers in some studies, though no consistent superiority over metformin is established. Combined myo-/D-chiro-inositol preparations exploit tissue-specific physiological ratios and are supported by some trial data for combined reproductive and metabolic benefit in PCOS. Direct head-to-head superiority over pharmacological treatments has not been consistently demonstrated across outcomes.
Compound variations
Myo-inositol
The most abundant and most studied supplemental form; the primary choice for PCOS and metabolic studies.
Common use case
PCOS, ovulation support, insulin sensitivity
Dosage note
Standard clinical dose: 2 g twice daily (total 4 g/day).
D-chiro-inositol
A stereoisomer with distinct roles in insulin signaling; studied alone and in combination with myo-inositol for PCOS and metabolic outcomes.
Common use case
Metabolic aspects of insulin resistance; combined regimens for PCOS
Dosage note
Typical single-agent dose in trials: ~600 mg/day; formulations vary.
Myo/D-chiro combination (40:1 ratio)
Fixed-ratio preparations (most commonly 40:1 myo:D-chiro) intended to approximate physiological tissue balance and address both reproductive and metabolic PCOS features.
Common use case
PCOS with both reproductive and metabolic treatment goals
Dosage note
Most studied at a total myo-inositol equivalent of 2–4 g/day with proportional D-chiro-inositol; follow product-specific labeling.
Inositol hexaphosphate (IP6 / phytic acid)
A highly phosphorylated plant-derived form found in seeds and bran. Has different biological properties and is not interchangeable with free myo-inositol for PCOS or anxiety indications.
Common use case
Different research applications; not standard for PCOS or anxiety
Dosage note
Dosing and indications differ substantially from free inositol; consult specific product literature.
Dosage and best practices
Dosage principles
- PCOS / ovulation: 2 g taken twice daily (total 4 g/day) for at least 2–3 months is the regimen used in the majority of randomized trials.
- Insulin sensitivity / gestational diabetes prevention: 4 g/day (commonly 2 g twice daily) is the typical research dose; higher doses have been explored but are not standard.
- Anxiety / panic disorder: Clinical trials used 12–18 g/day in divided doses. These are experimental doses associated with more gastrointestinal adverse effects and should only be used under clinician supervision.
Best practices
- Take myo-inositol with meals to reduce gastrointestinal discomfort; dividing the total daily dose (e.g., twice daily) is standard practice.
- In PCOS or fertility contexts, allow 8–12 weeks before evaluating changes in cycle regularity, ovulation, or metabolic markers.
- Choose preparations with clearly labeled myo-inositol content. Combined myo-/D-chiro-inositol products vary in ratio; a 40:1 myo:D-chiro ratio is the most commonly studied formulation.
Literature and references
Myo-Inositol — PubChem Compound Summary
PubChem, National Library of Medicine • 2024
Chemical and biological reference entry for myo-inositol including structure, physicochemical properties, and links to biomedical literature.
Inositol — Evidence and dosing summary
Examine.com • 2024
Aggregated evidence, mechanisms, and dosing references for inositol across uses including PCOS and psychiatric trials.
PubMed search: myo-inositol PCOS randomized controlled trials
PubMed, National Library of Medicine • 2024
Index of clinical trials and systematic reviews examining myo-inositol (typically 4 g/day) for ovulation, cycle regularity, and metabolic markers in PCOS.
PubMed search: inositol trisphosphate IP3 calcium signaling
PubMed, National Library of Medicine • 2024
Access point for foundational and review literature on phosphatidylinositol and IP3 signaling, including Berridge's landmark work on calcium mobilization.
Common questions
Is inositol the same as a vitamin?
Inositol is sometimes informally called 'vitamin B8,' but it is not classified as an essential vitamin because the body synthesizes it endogenously. It is considered a conditionally important nutrient in some metabolic contexts.
How long before I see effects for PCOS?
Trials typically detect changes in ovulation rate, cycle regularity, or metabolic markers after 8–12 weeks of continuous supplementation at 4 g/day. Individual responses vary.
Can I take myo-inositol with metformin?
Some clinicians combine them for PCOS. Both affect insulin and glucose metabolism, so blood glucose should be monitored and combined use discussed with a clinician.
Are myo- and D-chiro-inositol interchangeable?
No. They are stereoisomers with distinct tissue distributions and biological roles. Myo-inositol is the most abundant form and is used alone in most trials; D-chiro-inositol and combination formulations target different or overlapping aspects of insulin signaling and reproduction.
Is high-dose inositol safe for anxiety?
Doses of 12–18 g/day used in panic disorder trials are experimental and cause more gastrointestinal side effects than standard doses. Discuss this use with a clinician before attempting high-dose regimens.